Century Therapeutics, Inc. financial data

Symbol
IPSC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
25 N 38 Th Street, 11 Th Floor, Philadelphia, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 968 % -22.3%
Debt-to-equity 83.7 % +47.7%
Return On Equity -64.4 % -63.7%
Return On Assets -35 % -39.6%
Operating Margin -10.6 K % -385%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82.8 M shares +39.1%
Common Stock, Shares, Outstanding 60.3 M shares +2.08%
Entity Public Float 132 M USD -64.2%
Common Stock, Value, Issued 6 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62.3 M shares +6.29%
Weighted Average Number of Shares Outstanding, Diluted 57.8 M shares +78.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.37 M USD -76.6%
General and Administrative Expense 34.5 M USD +3.25%
Operating Income (Loss) -146 M USD -13.5%
Nonoperating Income (Expense) 13 M USD +60.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -133 M USD -7.62%
Income Tax Expense (Benefit) 674 K USD -47.5%
Net Income (Loss) Attributable to Parent -133 M USD -7.05%
Earnings Per Share, Basic -2.22 USD/shares -3.74%
Earnings Per Share, Diluted -2.27 USD/shares +23.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.8 M USD -46.1%
Other Assets, Current 1.57 M USD
Assets, Current 200 M USD -21.9%
Property, Plant and Equipment, Net 69 M USD -19.6%
Operating Lease, Right-of-Use Asset 19.3 M USD -31.5%
Assets 349 M USD -23.6%
Accounts Payable, Current 3.43 M USD -1.24%
Employee-related Liabilities, Current 2.87 M USD -8.63%
Accrued Liabilities, Current 721 K USD
Liabilities, Current 16.1 M USD -42%
Deferred Income Tax Liabilities, Net 10.4 M USD -8.1%
Operating Lease, Liability, Noncurrent 44.3 M USD +7.49%
Liabilities 171 M USD -4.71%
Accumulated Other Comprehensive Income (Loss), Net of Tax -241 K USD +81.1%
Retained Earnings (Accumulated Deficit) -684 M USD -24.3%
Stockholders' Equity Attributable to Parent 178 M USD -35.8%
Liabilities and Equity 349 M USD -23.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.2 M USD -3.52%
Net Cash Provided by (Used in) Financing Activities 18.2 M USD +3961%
Net Cash Provided by (Used in) Investing Activities 11.5 M USD -63.2%
Common Stock, Shares Authorized 300 M shares +140%
Common Stock, Shares, Issued 64.8 M shares +9.65%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 48.8 M USD -45.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 345 K USD +45%
Deferred Tax Assets, Valuation Allowance 127 M USD +62.4%
Deferred Tax Assets, Gross 138 M USD +53.6%
Operating Lease, Liability 46.5 M USD +11.3%
Depreciation 13.4 M USD +31.2%
Payments to Acquire Property, Plant, and Equipment 539 K USD -89.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -132 M USD -7.4%
Lessee, Operating Lease, Liability, to be Paid 81.9 M USD -10.7%
Property, Plant and Equipment, Gross 95 M USD -7.21%
Operating Lease, Liability, Current 2.22 M USD +283%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.42 M USD -1.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.9 M USD -27%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +11.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 27.4 M USD -40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.93 M USD -9.12%
Deferred Tax Assets, Operating Loss Carryforwards 31.1 M USD -11.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.13 M USD -8.76%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 10.4 M USD -8.06%
Share-based Payment Arrangement, Expense 3.21 M USD -15.5%
Interest Expense 913 K USD -29.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%